as of 12-15-2025 3:38pm EST
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | MORRISVILLE |
| Market Cap: | 2.5B | IPO Year: | 2018 |
| Target Price: | $37.40 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.37 - $35.54 | Next Earning Date: | 11-03-2025 |
| Revenue: | $69,216,000 | Revenue Growth: | 343.41% |
| Revenue Growth (this year): | 904.79% | Revenue Growth (next year): | 188.25% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Chief Commercial Officer
Avg Cost/Share
$32.19
Shares
831
Total Value
$26,749.89
Owned After
154,506
SEC Form 4
CFO and COO
Avg Cost/Share
$32.19
Shares
1,166
Total Value
$37,533.54
Owned After
353,823
SEC Form 4
Chief Business Officer
Avg Cost/Share
$32.19
Shares
693
Total Value
$22,307.67
Owned After
175,868
SEC Form 4
General Counsel
Avg Cost/Share
$32.19
Shares
1,072
Total Value
$34,507.68
Owned After
577,288
SEC Form 4
Chief Human Resource Officer
Avg Cost/Share
$32.19
Shares
221
Total Value
$7,113.99
Owned After
141,218
SEC Form 4
Chief Accounting Officer
Avg Cost/Share
$32.19
Shares
303
Total Value
$9,753.57
Owned After
155,031
SEC Form 4
Chief Business Officer
Avg Cost/Share
$30.03
Shares
35,656
Total Value
$1,070,710.46
Owned After
175,868
SEC Form 4
Chief Accounting Officer
Avg Cost/Share
$25.11
Shares
29,004
Total Value
$727,674.44
Owned After
155,031
Chief Medical Officer
Avg Cost/Share
$27.00
Shares
71,381
Total Value
$1,927,287.00
Owned After
243,012
Chief Business Officer
Avg Cost/Share
$22.93
Shares
692
Total Value
$15,867.56
Owned After
175,868
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Moomaw Scott | LQDA | Chief Commercial Officer | Dec 1, 2025 | Sell | $32.19 | 831 | $26,749.89 | 154,506 | |
| Kaseta Michael | LQDA | CFO and COO | Dec 1, 2025 | Sell | $32.19 | 1,166 | $37,533.54 | 353,823 | |
| Adair Jason | LQDA | Chief Business Officer | Dec 1, 2025 | Sell | $32.19 | 693 | $22,307.67 | 175,868 | |
| Schundler Russell | LQDA | General Counsel | Dec 1, 2025 | Sell | $32.19 | 1,072 | $34,507.68 | 577,288 | |
| Krepp Sarah | LQDA | Chief Human Resource Officer | Dec 1, 2025 | Sell | $32.19 | 221 | $7,113.99 | 141,218 | |
| Boyle Dana | LQDA | Chief Accounting Officer | Dec 1, 2025 | Sell | $32.19 | 303 | $9,753.57 | 155,031 | |
| Adair Jason | LQDA | Chief Business Officer | Nov 18, 2025 | Sell | $30.03 | 35,656 | $1,070,710.46 | 175,868 | |
| Boyle Dana | LQDA | Chief Accounting Officer | Nov 7, 2025 | Sell | $25.11 | 29,004 | $727,674.44 | 155,031 | |
| Saggar Rajeev | LQDA | Chief Medical Officer | Nov 5, 2025 | Sell | $27.00 | 71,381 | $1,927,287.00 | 243,012 | |
| Adair Jason | LQDA | Chief Business Officer | Oct 27, 2025 | Sell | $22.93 | 692 | $15,867.56 | 175,868 |
See how LQDA stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "LQDA Liquidia Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.